Loading
A Seattle safety and dose trial of helper T cells grown from patients' own blood, in women with advanced ovarian or peritoneal cancer. It ran from 2004 to 2010.
The registry describes a phase I study of the side effects and best dose of autologous CD4+ antigen-specific T-cell clones in stage III or IV ovarian or primary peritoneal cancer, started in October 2004 and completed in March 2010, with an estimated enrolment of 18 (ClinicalTrials.gov NCT00101257). Cassian Yee is listed as study chair and Fred Hutchinson Cancer Center as sponsor (ClinicalTrials.gov NCT00101257). No results are posted.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/